MCID: NRL005
MIFTS: 64

Neurilemmoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neurilemmoma

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 49 55 41 14 69
Schwannoma 12 49 28 51
Benign Schwannoma 49 55 69
Peripheral Fibroblastoma 49 55
Neurilemoma 49 55
Psammomatous Schwannoma 12
Neurolemmoma 49

Characteristics:

Orphanet epidemiological data:

55
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3192
MeSH 41 D009442
NCIt 46 C3269
Orphanet 55 ORPHA252164
UMLS via Orphanet 70 C0027809 C0854906

Summaries for Neurilemmoma

NIH Rare Diseases : 49 A schwannoma is a tumor of the peripheral nervous system or nerve root. A schwannoma develops from cells called Schwann cells, a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant schwannoma). Symptoms of a schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), schwannomatosis, or Carney complex. People with these genetic disorders usually have more than one schwannoma. Schwannomas may be diagnosed using imaging studies. A biopsy may confirm the diagnosis. Treatment of benign schwannomas may involve surgery to remove the tumor. Treatment of malignant schwannomas may include both surgery and radiation therapy. Last updated: 12/6/2017

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to schwannomatosis 1 and neurilemmomatosis, and has symptoms including abnormality of parotid gland, hearing abnormality and abnormality of the breast. An important gene associated with Neurilemmoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Cytoskeletal Signaling and Neuroscience. The drugs Anti-Bacterial Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 A schwannoma is a usually-benign nerve sheath tumor composed of Schwann cells, which normally produce... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 schwannomatosis 1 32.6 NF2 SMARCB1
2 neurilemmomatosis 32.2 NF1 NF2 PRKAR1A SMARCB1
3 cellular schwannoma 31.6 NF1 NF2 NGFR S100B SOX10
4 plexiform schwannoma 31.2 ENO2 GFAP KIT NF1 NF2 NGFR
5 malignant peripheral nerve sheath tumor 29.9 KIT NF1 NF2 PDGFRA S100B SMARCB1
6 oligodendroglioma 29.7 ENO2 GFAP PDGFRA
7 neuroma 29.5 ENO2 GFAP NF2 S100B SMARCB1
8 neurofibroma 29.5 KIT NF1 NF2 PDGFRA S100B SOX10
9 neurofibromatosis, type iv, of riccardi 29.4 KIT NF1 NF2 PDGFRA S100B
10 pleomorphic adenoma 29.4 GFAP S100B VIM
11 astrocytoma 28.5 GFAP NES NF1 S100B VIM
12 meningioma, familial 28.4 EZR GFAP MSN NF1 NF2 S100B
13 leiomyosarcoma 28.1 DES ENO2 KIT PDGFRA S100B VIM
14 mediastinal neurilemmoma 11.9
15 sympathetic neurilemmoma 11.9
16 melanotic neurilemmoma 11.9
17 neurilemmoma of the fifth cranial nerve 11.9
18 macrocystic neurilemmoma 11.8
19 mediastinal melanocytic neurilemmoma 11.8
20 neurilemmoma of the pleura 11.8
21 benign dermal neurilemmoma 11.8
22 benign mediastinal psammomatous neurilemmoma 11.8
23 benign mediastinal neurilemmoma 11.8
24 acoustic neuroma 11.2
25 schwannoma of jugular foramen 10.8
26 neurofibromatosis, familial spinal 10.6 NF1 NF2
27 monosomy 22 10.6 NF2 SMARCB1
28 gliofibroma 10.6 GFAP NF1
29 cerebral convexity meningioma 10.5 GFAP NF2
30 lung meningioma 10.5 ENO2 NF2
31 intraventricular meningioma 10.5 GFAP NF2
32 deep leiomyoma 10.5 GFAP KIT
33 large cell carcinoma with rhabdoid phenotype 10.5 ENO2 SMARCB1
34 cornea cancer 10.5 GFAP NF2
35 meningothelial meningioma 10.5 ENO2 NF2
36 neurofibrosarcoma 10.5 NF1 NF2
37 cutaneous ganglioneuroma 10.5 ENO2 KIT
38 duodenal somatostatinoma 10.5 ENO2 NF1
39 mixed type thymoma 10.5 KIT S100B
40 gemistocytic astrocytoma 10.5 GFAP S100B
41 middle cerebral artery infarction 10.4 ENO2 S100B
42 nodular medulloblastoma 10.4 GFAP SMARCB1
43 cerebellar medulloblastoma 10.4 ENO2 GFAP
44 kidney rhabdoid cancer 10.4 ENO2 SMARCB1
45 cerebellopontine angle tumor 10.4 GFAP NF2 SMARCB1
46 spinal cord ependymoma 10.4 GFAP NF1 NF2
47 spinal canal and spinal cord meningioma 10.4 ENO2 NF1 NF2
48 spinal meningioma 10.4 ENO2 NF1 NF2
49 autosomal genetic disease 10.4 NF1 NF2 PRKAR1A
50 spinal cancer 10.4 GFAP NF2

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

Human phenotypes related to Neurilemmoma:

55 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of parotid gland 55 31 occasional (7.5%) Occasional (29-5%) HP:0000197
2 hearing abnormality 55 31 frequent (33%) Frequent (79-30%) HP:0000364
3 abnormality of the breast 55 31 occasional (7.5%) Occasional (29-5%) HP:0000769
4 abnormality of the adrenal glands 55 31 occasional (7.5%) Occasional (29-5%) HP:0000834
5 abnormality of the liver 55 31 occasional (7.5%) Occasional (29-5%) HP:0001392
6 abnormality of the larynx 55 31 occasional (7.5%) Occasional (29-5%) HP:0001600
7 morphological abnormality of the central nervous system 55 31 occasional (7.5%) Occasional (29-5%) HP:0002011
8 abnormality of esophagus morphology 55 31 occasional (7.5%) Occasional (29-5%) HP:0002031
9 vertigo 55 31 frequent (33%) Frequent (79-30%) HP:0002321
10 acute episodes of neuropathic symptoms 55 31 occasional (7.5%) Occasional (29-5%) HP:0003489
11 vestibular schwannoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0009588
12 peripheral schwannoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0009593
13 abnormality of the temporal bone 55 31 hallmark (90%) Very frequent (99-80%) HP:0009911
14 facial palsy 55 31 frequent (33%) Frequent (79-30%) HP:0010628
15 abnormality of the twelfth cranial nerve 55 31 occasional (7.5%) Occasional (29-5%) HP:0010826
16 abnormality of peripheral nervous system electrophysiology 55 31 hallmark (90%) Very frequent (99-80%) HP:0030177
17 allodynia 55 31 frequent (33%) Frequent (79-30%) HP:0012533
18 scleral schwannoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0100011
19 nasal polyposis 55 31 occasional (7.5%) Occasional (29-5%) HP:0100582
20 intestinal polyposis 55 31 occasional (7.5%) Occasional (29-5%) HP:0200008
21 abnormality of the cranial nerves 55 Very frequent (99-80%)
22 abnormality of the fibula 55 Occasional (29-5%)
23 pain 55 Occasional (29-5%)
24 schwannoma 55 Very frequent (99-80%)
25 neurofibrosarcoma 55 Excluded (0%)
26 abnormality of fibula morphology 31 occasional (7.5%) HP:0002991

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

25 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.33 PDGFRA
2 Decreased viability GR00221-A-1 10.33 PRKAR1A KIT SMARCB1 NF1 PDGFRA
3 Decreased viability GR00221-A-2 10.33 PRKAR1A SMARCB1 NF1
4 Decreased viability GR00221-A-3 10.33 PRKAR1A SMARCB1 NF2 PDGFRA
5 Decreased viability GR00221-A-4 10.33 PRKAR1A NF1 PDGFRA
6 Decreased viability GR00301-A 10.33 KIT
7 Decreased viability GR00381-A-1 10.33 SMARCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 SMARCB1 VIM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 SOX10 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 S100B VIM
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 SOX10 KIT S100B SMARCB1 VIM
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
37 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Neurilemmoma:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 SMARCB1 SOX10 S100B VIM NF1 KIT
2 cellular MP:0005384 10.3 VIM SMARCB1 PRKAR1A SOX10 GFAP NF1
3 homeostasis/metabolism MP:0005376 10.27 VIM SMARCB1 PRKAR1A SOX10 S100B GFAP
4 growth/size/body region MP:0005378 10.25 SMARCB1 PRKAR1A SOX10 GFAP ENO2 KIT
5 cardiovascular system MP:0005385 10.22 VIM SMARCB1 PRKAR1A GFAP DES KIT
6 mortality/aging MP:0010768 10.21 VIM SMARCB1 PRKAR1A SOX10 GFAP NF1
7 digestive/alimentary MP:0005381 10.19 SMARCB1 SOX10 GFAP NF1 KIT EZR
8 immune system MP:0005387 10.18 VIM SMARCB1 PRKAR1A GFAP KIT EZR
9 embryo MP:0005380 10.13 VIM SMARCB1 PRKAR1A SOX10 KIT NF2
10 craniofacial MP:0005382 10.09 PRKAR1A ENO2 KIT NF1 NGFR NF2
11 integument MP:0010771 10.06 PRKAR1A SOX10 S100B KIT NF2 PDGFRA
12 muscle MP:0005369 10.06 VIM SMARCB1 PRKAR1A GFAP NF1 DES
13 nervous system MP:0003631 10.02 VIM SMARCB1 SOX10 GFAP ENO2 KIT
14 neoplasm MP:0002006 9.91 SMARCB1 PRKAR1A SOX10 NF1 KIT NF2
15 normal MP:0002873 9.91 PRKAR1A SOX10 S100B MSN GFAP NF1
16 respiratory system MP:0005388 9.61 SOX10 VIM NF1 KIT ENO2 NGFR
17 pigmentation MP:0001186 9.55 PRKAR1A SOX10 KIT PDGFRA NF1
18 vision/eye MP:0005391 9.23 VIM SMARCB1 PRKAR1A GFAP KIT NF1

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
3 Gentamicins Phase 4
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
12 Antiemetics Phase 3
13 Anti-Inflammatory Agents Phase 3,Phase 2
14 Antineoplastic Agents, Hormonal Phase 3
15 Autonomic Agents Phase 3
16 Gastrointestinal Agents Phase 3
17 glucocorticoids Phase 3
18 Hormone Antagonists Phase 3
19 Hormones Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
21 Methylprednisolone acetate Phase 3
22 Methylprednisolone Hemisuccinate Phase 3
23 Neuroprotective Agents Phase 3
24 Peripheral Nervous System Agents Phase 3,Phase 2
25 Prednisolone acetate Phase 3
26 Prednisolone hemisuccinate Phase 3
27 Prednisolone phosphate Phase 3
28 Protective Agents Phase 3,Phase 2
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
31 Isophosphamide mustard Phase 3,Phase 2 0
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Imatinib Mesylate Phase 2, Phase 3 123596
34
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
35
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
36
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
38
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
39
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
40
Etoposide Approved Phase 2 33419-42-0 36462
41
Lenograstim Approved, Investigational Phase 2 135968-09-1
42
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
45
nivolumab Approved Phase 2 946414-94-4
46
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
47
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 97)

# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
7 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
8 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
9 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
13 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
18 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
19 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
20 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
21 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
22 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
24 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
25 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
26 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
27 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
28 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
29 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
30 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
31 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
32 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
33 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
34 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
35 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
36 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
37 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
38 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
39 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
40 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
41 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
42 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
43 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
44 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib
45 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2 PTC299
46 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
47 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
49 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Genetic tests related to Neurilemmoma:

# Genetic test Affiliating Genes
1 Schwannoma 28

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

38
Tongue, Bone, Brain, Breast, Thyroid, Liver, Adrenal Gland

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 458)
# Title Authors Year
1
A Rare Case of Primary Intrapulmonary Neurilemmoma Diagnosed in a 43-Year-Old Asymptomatic Man with a Well-defined Intrapulmonary Mass. ( 29441326 )
2018
2
Experience of operative treatment in 27 patients with intraspinal neurilemmoma. ( 29085485 )
2017
3
Erratum: Affiliation and corresponding author correction: Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28480189 )
2017
4
Surgical management of a large neurilemmoma-like leiomyoma of the uterine cervix mimicking a retroperitoneal tumor. ( 28702500 )
2017
5
Neurilemmoma of Maxillary Alveolus: A Rare Case Report and Review of Literature. ( 29284981 )
2017
6
Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28289669 )
2017
7
Intraoral neurilemmoma of mental nerve mimicking as traumatic fibroma: An unusual presentation - A case report and literature review. ( 28479699 )
2017
8
Neurilemmoma Of External Ear, Confirmed By Immunohistochemistry-A Telepathological Communication Between Cyprus And India. ( 28828767 )
2016
9
Cervical vagus nerve neurilemmoma mimicking parathyroid adenoma. ( 27562903 )
2016
10
Neurilemmoma in the floor of the mouth: a case report. ( 26904498 )
2016
11
Recurrent Ancient Intraosseous Neurilemmoma of Maxilla: A Rare Case Report. ( 27499782 )
2016
12
Intraventricular Neurilemmoma (Schwannoma): Shall GFAP Immunostaining Be Regarded as a Histogenetical Tag or as a Mere Histomimetical Trait? ( 27446622 )
2016
13
Schwannoma (Neurilemmoma) on the Base of the Tongue: A Rare Clinical Case. ( 27018477 )
2016
14
Neurilemmoma of the Vagus Nerve in the Poststyloid Parapharyngeal Space. ( 26894190 )
2016
15
Neurilemmoma of Deep Peroneal Nerve Sensory Branch : Thermographic Findings with Compression Test. ( 26539275 )
2015
16
Benign paravertebral ancient neurilemmoma in a young adult: a rare occurrence. ( 25738029 )
2015
17
Vaginal Neurilemmoma: Case Report with Brief Review. ( 27217689 )
2015
18
Neurilemmoma of Retromolar Region in the Oral Cavity. ( 26221545 )
2015
19
Thoracic Neurilemmoma Presenting With Spinal Nerve Involvement in Promyelocytic Leukemia. ( 25950139 )
2015
20
Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule. ( 26498011 )
2015
21
Surgical outcome of spinal neurilemmoma: two case reports. ( 25654395 )
2015
22
Intestinal neurilemmoma. ( 24157416 )
2014
23
Neurilemmoma of median nerve. ( 25983466 )
2014
24
Neurilemmoma of lateral nasal wall. ( 25179720 )
2014
25
Penile neurilemmoma: Utility of fine-needle aspiration cytology in diagnosis of a rare entity. ( 25538392 )
2014
26
Intraosseous neurilemmoma of the proximal ulna. ( 25460435 )
2014
27
Laparoscopic phrenectomy for a diaphragmatic neurilemmoma. ( 24250705 )
2013
28
Ancient neurilemmoma: A rare oral tumor. ( 24574671 )
2013
29
Maxillary neurilemmoma-Rarest of the rare tumour: Report of 2 cases. ( 24129122 )
2013
30
Lateral cervical approach combined with posterior thoracotomy for the treatment of giant neurilemmoma of the chest involving the neck. ( 22884113 )
2013
31
Neurilemmoma Showing a Unique Growth Pattern in the Lateral Chest Wall: Both Inside and Outside the Thoracic Cavity. ( 23445787 )
2013
32
Human pulmonary dirofilariasis coexisting with intercostal neurilemmoma: a case report and literature review. ( 24080016 )
2013
33
Hibernoma in the thoracic back muscle accompanied by neurilemmoma. ( 25983847 )
2012
34
Giant neurilemmoma of the vagus nerve: a case report and review of literature. ( 23936960 )
2012
35
Neurilemmoma of the thyroid gland. ( 22728508 )
2012
36
Rectal schwannoma (neurilemmoma). ( 22369805 )
2012
37
Value of ultrasonography in neurilemmoma diagnosis: the role of round shape morphology. ( 22957323 )
2012
38
Multiple neurilemmomas in Birt-Hogg-DubAc syndrome: case report. ( 22326190 )
2012
39
Mesentery neurilemmoma: CT, MRI and angiographic findings. ( 22041360 )
2011
40
Lower neck neurilemmoma can masquerade as lymph node metastasis on FDG PET/CT in patient with nasopharyngeal carcinoma. ( 22064115 )
2011
41
Intraosseous neurilemmoma of the mandible: report of a rare ancient type. ( 22013479 )
2011
42
Neurilemmoma presenting as a midline nasal mass in a pediatric patient. ( 20461682 )
2010
43
Dermal schwannoma (neurilemmoma): a peculiar foreign body reaction? ( 20216197 )
2010
44
Neurilemmoma (schwannoma) of the thyroid gland: a rare case presentation. ( 21045459 )
2010
45
Mandible schwannoma (neurilemmoma) presenting as periapical lesion. ( 19225090 )
2009
46
Intranodal neurilemmoma presenting as parotid mass. ( 18940018 )
2009
47
Neurilemmoma of the first branch of the lateral plantar nerve causing tarsal tunnel syndrome. ( 20400427 )
2009
48
Fibroadenoma with digital fibroma-like inclusions in neurilemmoma-like stromal component. ( 18186878 )
2008
49
Wagner-Meissner neurilemmoma of the right cheek. ( 18486897 )
2008
50
Multinodular neurilemmoma of the tongue: a case report with differential immunohistochemical profile. ( 18427374 )
2008

Variations for Neurilemmoma

Copy number variations for Neurilemmoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ruffle GO:0001726 9.67 EZR NF2 S100B
2 apical part of cell GO:0045177 9.65 EZR MSN NF2
3 cell body GO:0044297 9.58 EZR GFAP NF2
4 filopodium GO:0030175 9.5 EZR MSN NF2
5 cytoplasm GO:0005737 9.47 DES ENO2 EZR GFAP KIT MSN
6 uropod GO:0001931 9.46 EZR MSN
7 intermediate filament GO:0005882 9.46 DES GFAP NES VIM
8 invadopodium GO:0071437 9.43 EZR MSN
9 intermediate filament cytoskeleton GO:0045111 9.43 DES GFAP NES
10 astrocyte projection GO:0097449 9.37 EZR GFAP
11 myelin sheath GO:0043209 9.26 ENO2 EZR GFAP MSN

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.74 NF1 NF2 PRKAR1A
2 positive regulation of gene expression GO:0010628 9.72 EZR KIT MSN SOX10 VIM
3 negative regulation of neuron projection development GO:0010977 9.61 GFAP NGFR VIM
4 melanocyte differentiation GO:0030318 9.59 KIT SOX10
5 negative regulation of cell-matrix adhesion GO:0001953 9.58 NF1 NF2
6 astrocyte development GO:0014002 9.58 GFAP VIM
7 establishment of endothelial barrier GO:0061028 9.56 EZR MSN
8 establishment of epithelial cell apical/basal polarity GO:0045198 9.55 EZR MSN
9 positive regulation of myelination GO:0031643 9.54 S100B SOX10
10 positive regulation of cellular protein catabolic process GO:1903364 9.52 EZR MSN
11 positive regulation of phospholipase C activity GO:0010863 9.51 KIT PDGFRA
12 gland morphogenesis GO:0022612 9.49 EZR MSN
13 Bergmann glial cell differentiation GO:0060020 9.48 GFAP VIM
14 positive regulation of early endosome to late endosome transport GO:2000643 9.46 EZR MSN
15 regulation of cell shape GO:0008360 9.46 EZR KIT MSN S100B
16 positive regulation of protein localization to early endosome GO:1902966 9.4 EZR MSN
17 membrane to membrane docking GO:0022614 9.37 EZR MSN
18 regulation of organelle assembly GO:1902115 9.26 EZR MSN
19 intermediate filament-based process GO:0045103 8.96 GFAP VIM
20 intermediate filament organization GO:0045109 8.8 DES GFAP VIM

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A catalytic subunit binding GO:0034236 9.32 EZR PRKAR1A
2 S100 protein binding GO:0044548 9.26 EZR S100B
3 structural constituent of cytoskeleton GO:0005200 9.26 DES GFAP MSN VIM
4 cytoskeletal protein binding GO:0008092 8.92 DES EZR MSN NF2
5 protein binding GO:0005515 10.03 DES ENO2 EZR GFAP KIT MSN

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....